| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Diabetes Mellitus, Type 1 | 56 | 2025 | 630 | 6.080 |
Why?
|
| Islets of Langerhans Transplantation | 32 | 2019 | 179 | 5.550 |
Why?
|
| Islets of Langerhans | 42 | 2025 | 286 | 4.240 |
Why?
|
| Insulin-Secreting Cells | 24 | 2025 | 195 | 3.330 |
Why?
|
| Insulin | 39 | 2022 | 696 | 3.210 |
Why?
|
| Diabetes Mellitus | 15 | 2022 | 555 | 2.800 |
Why?
|
| Immunosuppressive Agents | 22 | 2011 | 381 | 1.940 |
Why?
|
| B7-1 Antigen | 16 | 2014 | 74 | 1.670 |
Why?
|
| Blood Glucose | 20 | 2017 | 502 | 1.440 |
Why?
|
| Diabetes Mellitus, Experimental | 10 | 2019 | 206 | 1.370 |
Why?
|
| T-Lymphocytes | 26 | 2025 | 1010 | 1.320 |
Why?
|
| Hypoglycemia | 7 | 2017 | 64 | 1.150 |
Why?
|
| Antibodies, Monoclonal | 20 | 2009 | 875 | 1.100 |
Why?
|
| Sirolimus | 8 | 2011 | 93 | 1.100 |
Why?
|
| Hypoglycemic Agents | 12 | 2016 | 225 | 1.060 |
Why?
|
| CD40 Ligand | 20 | 2005 | 159 | 0.970 |
Why?
|
| Graft Rejection | 15 | 2003 | 304 | 0.940 |
Why?
|
| Kidney Transplantation | 15 | 2009 | 326 | 0.760 |
Why?
|
| Membrane Glycoproteins | 15 | 2002 | 667 | 0.730 |
Why?
|
| Animals | 86 | 2024 | 21467 | 0.700 |
Why?
|
| C-Peptide | 11 | 2016 | 24 | 0.690 |
Why?
|
| Humans | 115 | 2025 | 65654 | 0.650 |
Why?
|
| Glucose | 7 | 2014 | 478 | 0.630 |
Why?
|
| Autoimmunity | 8 | 2019 | 249 | 0.590 |
Why?
|
| Graft Survival | 15 | 2019 | 300 | 0.570 |
Why?
|
| Transcriptome | 4 | 2024 | 405 | 0.570 |
Why?
|
| Lymphocyte Activation | 15 | 2020 | 754 | 0.570 |
Why?
|
| Histocompatibility Antigens Class II | 2 | 2019 | 179 | 0.550 |
Why?
|
| Autoantigens | 5 | 2025 | 140 | 0.530 |
Why?
|
| Immunoglobulin G | 6 | 2009 | 472 | 0.530 |
Why?
|
| Venoms | 3 | 2014 | 11 | 0.520 |
Why?
|
| Immune System | 3 | 2002 | 132 | 0.500 |
Why?
|
| Endocrinologists | 1 | 2016 | 5 | 0.500 |
Why?
|
| Antigens, CD | 13 | 2002 | 344 | 0.480 |
Why?
|
| Macaca mulatta | 20 | 2015 | 261 | 0.470 |
Why?
|
| Mice | 45 | 2024 | 11174 | 0.470 |
Why?
|
| Physician's Role | 1 | 2016 | 122 | 0.460 |
Why?
|
| Promoter Regions, Genetic | 8 | 2014 | 689 | 0.450 |
Why?
|
| Peptides | 5 | 2025 | 593 | 0.440 |
Why?
|
| Health Care Costs | 1 | 2017 | 224 | 0.440 |
Why?
|
| Transplantation, Homologous | 16 | 2009 | 250 | 0.430 |
Why?
|
| CD4-Positive T-Lymphocytes | 7 | 2019 | 642 | 0.420 |
Why?
|
| CD28 Antigens | 6 | 2001 | 62 | 0.420 |
Why?
|
| Pancreas Transplantation | 4 | 2009 | 19 | 0.410 |
Why?
|
| Delivery of Health Care | 2 | 2017 | 439 | 0.400 |
Why?
|
| Autoantibodies | 2 | 2012 | 186 | 0.390 |
Why?
|
| CD3 Complex | 6 | 2005 | 63 | 0.390 |
Why?
|
| Antigen Presentation | 5 | 2025 | 239 | 0.390 |
Why?
|
| Quality Improvement | 2 | 2018 | 468 | 0.390 |
Why?
|
| Transplantation Immunology | 3 | 2001 | 26 | 0.370 |
Why?
|
| Transplantation Tolerance | 3 | 2001 | 69 | 0.370 |
Why?
|
| Biomedical Engineering | 2 | 2002 | 8 | 0.370 |
Why?
|
| Cytokines | 11 | 2025 | 964 | 0.370 |
Why?
|
| Cell Proliferation | 3 | 2015 | 1044 | 0.360 |
Why?
|
| Patient Care Planning | 1 | 2011 | 85 | 0.340 |
Why?
|
| Quality of Health Care | 2 | 2013 | 533 | 0.330 |
Why?
|
| Infant Formula | 1 | 2010 | 13 | 0.330 |
Why?
|
| Tacrolimus | 4 | 2003 | 63 | 0.330 |
Why?
|
| Mice, Transgenic | 13 | 2015 | 1291 | 0.330 |
Why?
|
| Antigens, Differentiation | 7 | 2000 | 144 | 0.330 |
Why?
|
| Rats | 10 | 2023 | 2002 | 0.320 |
Why?
|
| Gene Expression Regulation | 7 | 2018 | 1634 | 0.320 |
Why?
|
| Immunoconjugates | 6 | 2000 | 95 | 0.310 |
Why?
|
| Cells, Cultured | 14 | 2019 | 2193 | 0.310 |
Why?
|
| Glucagon | 4 | 2018 | 36 | 0.300 |
Why?
|
| Hematopoietic Stem Cells | 5 | 2002 | 300 | 0.300 |
Why?
|
| Glucagon-Secreting Cells | 3 | 2020 | 26 | 0.290 |
Why?
|
| Epitopes, T-Lymphocyte | 2 | 2018 | 186 | 0.280 |
Why?
|
| Obesity | 2 | 2015 | 1277 | 0.280 |
Why?
|
| Endocrinology | 2 | 2018 | 21 | 0.280 |
Why?
|
| Female | 41 | 2024 | 34310 | 0.270 |
Why?
|
| Alternative Splicing | 3 | 2004 | 140 | 0.270 |
Why?
|
| Flow Cytometry | 6 | 2009 | 664 | 0.260 |
Why?
|
| Hormones, Ectopic | 2 | 2004 | 3 | 0.260 |
Why?
|
| History, 20th Century | 3 | 2022 | 234 | 0.260 |
Why?
|
| Diabetes Mellitus, Type 2 | 6 | 2024 | 733 | 0.260 |
Why?
|
| T-Lymphocytes, Cytotoxic | 4 | 2007 | 169 | 0.260 |
Why?
|
| Portal Vein | 2 | 2009 | 39 | 0.260 |
Why?
|
| Adult | 29 | 2024 | 17511 | 0.250 |
Why?
|
| Transforming Growth Factor beta | 3 | 2009 | 181 | 0.250 |
Why?
|
| Antibodies | 3 | 2005 | 188 | 0.250 |
Why?
|
| Antilymphocyte Serum | 2 | 2003 | 22 | 0.250 |
Why?
|
| Tissue Transplantation | 3 | 2002 | 9 | 0.240 |
Why?
|
| CD8-Positive T-Lymphocytes | 7 | 2016 | 679 | 0.240 |
Why?
|
| Diabetic Nephropathies | 4 | 2014 | 38 | 0.240 |
Why?
|
| Time Factors | 15 | 2015 | 3777 | 0.240 |
Why?
|
| T-Lymphocyte Subsets | 4 | 2017 | 241 | 0.240 |
Why?
|
| Protein Biosynthesis | 3 | 2004 | 333 | 0.240 |
Why?
|
| Prediabetic State | 2 | 2023 | 54 | 0.230 |
Why?
|
| Male | 32 | 2024 | 31297 | 0.230 |
Why?
|
| Transcription, Genetic | 5 | 2018 | 909 | 0.230 |
Why?
|
| Antibodies, Monoclonal, Humanized | 11 | 2009 | 254 | 0.230 |
Why?
|
| Sequence Analysis, RNA | 3 | 2016 | 182 | 0.230 |
Why?
|
| Patient Satisfaction | 4 | 2024 | 442 | 0.230 |
Why?
|
| Signal Transduction | 11 | 2009 | 3164 | 0.230 |
Why?
|
| Mice, Inbred NOD | 7 | 2016 | 526 | 0.220 |
Why?
|
| Deoxyribonucleotides | 1 | 2024 | 13 | 0.210 |
Why?
|
| Liver | 4 | 2007 | 874 | 0.210 |
Why?
|
| Organoids | 1 | 2024 | 44 | 0.210 |
Why?
|
| RNA-Directed DNA Polymerase | 1 | 2024 | 39 | 0.210 |
Why?
|
| Lymphocyte Count | 2 | 2003 | 71 | 0.210 |
Why?
|
| Streptozocin | 3 | 2004 | 23 | 0.210 |
Why?
|
| Herpesvirus 1, Human | 1 | 2024 | 83 | 0.210 |
Why?
|
| Drug Therapy, Combination | 5 | 2009 | 463 | 0.210 |
Why?
|
| Prognosis | 5 | 2017 | 1791 | 0.210 |
Why?
|
| Pulmonary Artery | 1 | 2004 | 96 | 0.200 |
Why?
|
| Transplantation, Heterotopic | 2 | 2002 | 6 | 0.200 |
Why?
|
| Interferon-gamma | 9 | 2002 | 576 | 0.200 |
Why?
|
| Tumor Necrosis Factor-alpha | 8 | 2002 | 604 | 0.200 |
Why?
|
| Transplantation, Heterologous | 6 | 2019 | 241 | 0.200 |
Why?
|
| Self-Management | 1 | 2024 | 72 | 0.200 |
Why?
|
| RNA | 5 | 2023 | 427 | 0.190 |
Why?
|
| Tissue Donors | 5 | 2018 | 147 | 0.190 |
Why?
|
| Genetic Engineering | 1 | 2004 | 114 | 0.190 |
Why?
|
| Mice, Inbred C57BL | 13 | 2015 | 3501 | 0.190 |
Why?
|
| Immunotherapy | 1 | 2005 | 274 | 0.190 |
Why?
|
| Thioredoxins | 1 | 2002 | 17 | 0.190 |
Why?
|
| Proinsulin | 1 | 2002 | 3 | 0.190 |
Why?
|
| Organ Transplantation | 2 | 2001 | 46 | 0.190 |
Why?
|
| Celiac Artery | 1 | 2002 | 13 | 0.180 |
Why?
|
| Middle Aged | 19 | 2024 | 18440 | 0.180 |
Why?
|
| Immunoglobulin Fc Fragments | 3 | 2004 | 50 | 0.180 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 2 | 2003 | 297 | 0.180 |
Why?
|
| Feasibility Studies | 1 | 2024 | 593 | 0.180 |
Why?
|
| Gene Expression Profiling | 5 | 2019 | 797 | 0.180 |
Why?
|
| Insulin, Regular, Human | 1 | 2022 | 2 | 0.180 |
Why?
|
| Radiation Injuries, Experimental | 1 | 2002 | 9 | 0.180 |
Why?
|
| Lung Diseases, Interstitial | 1 | 2003 | 145 | 0.180 |
Why?
|
| Pulmonary Embolism | 1 | 2004 | 198 | 0.180 |
Why?
|
| Nobel Prize | 1 | 2022 | 13 | 0.180 |
Why?
|
| Endoplasmic Reticulum Stress | 2 | 2020 | 53 | 0.170 |
Why?
|
| Research Personnel | 1 | 2022 | 82 | 0.170 |
Why?
|
| Chronic Disease | 3 | 2017 | 744 | 0.170 |
Why?
|
| Epitopes | 2 | 2016 | 291 | 0.170 |
Why?
|
| Wound Healing | 1 | 2002 | 193 | 0.170 |
Why?
|
| Patient Education as Topic | 1 | 2024 | 489 | 0.160 |
Why?
|
| Tissue Engineering | 1 | 2002 | 148 | 0.160 |
Why?
|
| Young Adult | 10 | 2019 | 4855 | 0.160 |
Why?
|
| Pancreas, Exocrine | 1 | 2020 | 12 | 0.160 |
Why?
|
| Gene Editing | 1 | 2024 | 331 | 0.160 |
Why?
|
| Endocrine Cells | 1 | 2019 | 10 | 0.150 |
Why?
|
| Pluripotent Stem Cells | 1 | 2020 | 72 | 0.150 |
Why?
|
| Bromodeoxyuridine | 2 | 2010 | 44 | 0.150 |
Why?
|
| Macaca fascicularis | 3 | 2011 | 48 | 0.150 |
Why?
|
| Protein Precursors | 2 | 2014 | 85 | 0.150 |
Why?
|
| Immunotoxins | 1 | 1999 | 7 | 0.150 |
Why?
|
| Receptors, Antigen, T-Cell | 4 | 2009 | 281 | 0.150 |
Why?
|
| Pancreas | 4 | 2020 | 153 | 0.150 |
Why?
|
| Hepatocyte Nuclear Factor 1-alpha | 1 | 2018 | 12 | 0.140 |
Why?
|
| Hyperglycemia | 4 | 2013 | 109 | 0.140 |
Why?
|
| Brain | 2 | 2024 | 1625 | 0.140 |
Why?
|
| Gene Expression Regulation, Developmental | 2 | 2015 | 663 | 0.140 |
Why?
|
| Interferon Inducers | 1 | 1998 | 11 | 0.140 |
Why?
|
| Autoimmune Diseases | 4 | 2024 | 239 | 0.140 |
Why?
|
| Poly I-C | 1 | 1998 | 76 | 0.140 |
Why?
|
| Gene Expression | 6 | 2006 | 855 | 0.140 |
Why?
|
| MafB Transcription Factor | 2 | 2015 | 5 | 0.140 |
Why?
|
| Antibody Formation | 6 | 2002 | 111 | 0.140 |
Why?
|
| Self Care | 2 | 2024 | 218 | 0.130 |
Why?
|
| Proteins | 3 | 2006 | 764 | 0.130 |
Why?
|
| Genetic Variation | 2 | 2018 | 395 | 0.130 |
Why?
|
| Adolescent | 11 | 2018 | 6350 | 0.130 |
Why?
|
| Alzheimer Disease | 1 | 2024 | 768 | 0.130 |
Why?
|
| Economics, Medical | 1 | 2017 | 3 | 0.130 |
Why?
|
| Amino Acid Sequence | 4 | 2016 | 1589 | 0.130 |
Why?
|
| Skin Transplantation | 3 | 2003 | 154 | 0.130 |
Why?
|
| Cross-Over Studies | 3 | 2016 | 163 | 0.130 |
Why?
|
| Body Weight | 3 | 2013 | 377 | 0.130 |
Why?
|
| Pancreas, Artificial | 1 | 2016 | 2 | 0.130 |
Why?
|
| Primates | 4 | 2016 | 52 | 0.130 |
Why?
|
| Insulin Infusion Systems | 1 | 2016 | 10 | 0.130 |
Why?
|
| Arginine | 2 | 2011 | 136 | 0.130 |
Why?
|
| Lymphocytes | 4 | 2003 | 209 | 0.120 |
Why?
|
| Polymorphism, Genetic | 3 | 2002 | 199 | 0.120 |
Why?
|
| HLA-DQ Antigens | 1 | 2016 | 14 | 0.120 |
Why?
|
| Hormones | 1 | 2016 | 62 | 0.120 |
Why?
|
| Physician Assistants | 1 | 2016 | 40 | 0.120 |
Why?
|
| HLA-A2 Antigen | 1 | 2016 | 62 | 0.120 |
Why?
|
| Pancreatitis | 1 | 2017 | 96 | 0.120 |
Why?
|
| Antigen-Presenting Cells | 1 | 1997 | 180 | 0.120 |
Why?
|
| Protein Processing, Post-Translational | 1 | 2018 | 269 | 0.120 |
Why?
|
| Foreign-Body Reaction | 1 | 2016 | 16 | 0.120 |
Why?
|
| Academic Medical Centers | 1 | 2018 | 309 | 0.120 |
Why?
|
| Regeneration | 2 | 2009 | 126 | 0.120 |
Why?
|
| Dendritic Cells | 4 | 2016 | 531 | 0.120 |
Why?
|
| Swine | 5 | 2003 | 397 | 0.110 |
Why?
|
| Glycogen Synthase Kinase 3 | 1 | 2015 | 46 | 0.110 |
Why?
|
| Nurse Practitioners | 1 | 2016 | 122 | 0.110 |
Why?
|
| Prostheses and Implants | 1 | 2016 | 71 | 0.110 |
Why?
|
| Safety | 2 | 2009 | 142 | 0.110 |
Why?
|
| Postoperative Complications | 4 | 2009 | 1335 | 0.110 |
Why?
|
| Somatostatin-Secreting Cells | 1 | 2015 | 8 | 0.110 |
Why?
|
| Single-Cell Analysis | 1 | 2016 | 118 | 0.110 |
Why?
|
| Antigens, CD34 | 3 | 2000 | 53 | 0.110 |
Why?
|
| Foreign Bodies | 1 | 2016 | 56 | 0.110 |
Why?
|
| Models, Biological | 1 | 2020 | 1193 | 0.110 |
Why?
|
| Fibroblasts | 1 | 1997 | 423 | 0.110 |
Why?
|
| Molecular Sequence Data | 5 | 2016 | 1979 | 0.110 |
Why?
|
| Ultrasonography | 1 | 2017 | 491 | 0.110 |
Why?
|
| CD40 Antigens | 3 | 2005 | 59 | 0.110 |
Why?
|
| Fetus | 1 | 2015 | 103 | 0.110 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 4 | 2004 | 542 | 0.110 |
Why?
|
| B7-2 Antigen | 5 | 2002 | 32 | 0.110 |
Why?
|
| Eating | 3 | 2010 | 140 | 0.110 |
Why?
|
| Antigens, Surface | 2 | 1999 | 199 | 0.110 |
Why?
|
| Glucose-6-Phosphatase | 1 | 2014 | 15 | 0.110 |
Why?
|
| Hydrogels | 1 | 2016 | 127 | 0.100 |
Why?
|
| Insulinoma | 2 | 2004 | 5 | 0.100 |
Why?
|
| Epithelial Cells | 1 | 2016 | 414 | 0.100 |
Why?
|
| Drug Administration Schedule | 4 | 2013 | 296 | 0.100 |
Why?
|
| Patient-Centered Care | 1 | 2016 | 267 | 0.100 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 3 | 2011 | 355 | 0.100 |
Why?
|
| Organ Specificity | 1 | 2014 | 200 | 0.100 |
Why?
|
| Aging | 3 | 2010 | 775 | 0.100 |
Why?
|
| Base Sequence | 5 | 2004 | 1331 | 0.100 |
Why?
|
| Medical Records Systems, Computerized | 1 | 2013 | 62 | 0.100 |
Why?
|
| Peptide Fragments | 2 | 2007 | 418 | 0.100 |
Why?
|
| Endothelium | 3 | 2002 | 21 | 0.100 |
Why?
|
| Treatment Outcome | 5 | 2015 | 5820 | 0.100 |
Why?
|
| Disease Models, Animal | 6 | 2017 | 2327 | 0.100 |
Why?
|
| Nerve Tissue Proteins | 1 | 2015 | 428 | 0.100 |
Why?
|
| Apoptosis | 5 | 2017 | 1100 | 0.100 |
Why?
|
| Models, Immunological | 2 | 2003 | 85 | 0.090 |
Why?
|
| Diabetic Retinopathy | 1 | 2014 | 60 | 0.090 |
Why?
|
| Physicians | 1 | 2018 | 486 | 0.090 |
Why?
|
| United States | 4 | 2017 | 8166 | 0.090 |
Why?
|
| Gene Regulatory Networks | 1 | 2014 | 160 | 0.090 |
Why?
|
| Referral and Consultation | 2 | 2018 | 445 | 0.090 |
Why?
|
| Staining and Labeling | 2 | 2010 | 127 | 0.090 |
Why?
|
| Stomach | 1 | 2012 | 87 | 0.090 |
Why?
|
| Genome-Wide Association Study | 1 | 2014 | 364 | 0.090 |
Why?
|
| Maryland | 1 | 2011 | 36 | 0.090 |
Why?
|
| RNA, Messenger | 6 | 2004 | 1581 | 0.090 |
Why?
|
| Chromosomes, Human, Pair 6 | 1 | 1991 | 17 | 0.090 |
Why?
|
| Child | 7 | 2018 | 4634 | 0.090 |
Why?
|
| Age of Onset | 2 | 2009 | 174 | 0.090 |
Why?
|
| Glucose Tolerance Test | 1 | 2011 | 97 | 0.090 |
Why?
|
| DNA | 3 | 2014 | 853 | 0.090 |
Why?
|
| Kidney Failure, Chronic | 3 | 2009 | 197 | 0.080 |
Why?
|
| Biomarkers | 3 | 2015 | 1487 | 0.080 |
Why?
|
| Creatinine | 2 | 2009 | 136 | 0.080 |
Why?
|
| Vaccination | 1 | 2014 | 388 | 0.080 |
Why?
|
| Phenotype | 4 | 2018 | 1235 | 0.080 |
Why?
|
| Guidelines as Topic | 1 | 2011 | 159 | 0.080 |
Why?
|
| Radiometric Dating | 1 | 2010 | 1 | 0.080 |
Why?
|
| Primary Health Care | 1 | 2016 | 725 | 0.080 |
Why?
|
| Cytoplasm | 2 | 2009 | 283 | 0.080 |
Why?
|
| Caseins | 1 | 2010 | 42 | 0.080 |
Why?
|
| CTLA-4 Antigen | 6 | 2000 | 72 | 0.080 |
Why?
|
| Abatacept | 6 | 2000 | 67 | 0.080 |
Why?
|
| Epigenesis, Genetic | 1 | 2014 | 408 | 0.080 |
Why?
|
| Histones | 1 | 2014 | 497 | 0.080 |
Why?
|
| Pancreatic Neoplasms | 2 | 2004 | 354 | 0.080 |
Why?
|
| Immunohistochemistry | 4 | 2006 | 898 | 0.080 |
Why?
|
| Nuclease Protection Assays | 1 | 2009 | 3 | 0.080 |
Why?
|
| Cytotoxicity, Immunologic | 2 | 2020 | 138 | 0.080 |
Why?
|
| Monitoring, Immunologic | 1 | 2009 | 3 | 0.080 |
Why?
|
| HLA-DRB1 Chains | 1 | 2009 | 16 | 0.080 |
Why?
|
| HLA-DR Antigens | 1 | 2009 | 26 | 0.080 |
Why?
|
| Neoplasms | 2 | 2010 | 1376 | 0.080 |
Why?
|
| Kidney | 3 | 2002 | 458 | 0.080 |
Why?
|
| Diabetes Complications | 1 | 2010 | 106 | 0.080 |
Why?
|
| Nucleic Acid Conformation | 3 | 2004 | 241 | 0.070 |
Why?
|
| Hepatic Veins | 1 | 2009 | 13 | 0.070 |
Why?
|
| Von Hippel-Lindau Tumor Suppressor Protein | 1 | 2009 | 9 | 0.070 |
Why?
|
| Transduction, Genetic | 2 | 2009 | 242 | 0.070 |
Why?
|
| Leishmania major | 2 | 1999 | 8 | 0.070 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 1 | 1991 | 345 | 0.070 |
Why?
|
| Smad3 Protein | 1 | 2009 | 17 | 0.070 |
Why?
|
| Genetic Therapy | 2 | 2009 | 852 | 0.070 |
Why?
|
| Case-Control Studies | 3 | 2018 | 1144 | 0.070 |
Why?
|
| Insulin Resistance | 3 | 2013 | 415 | 0.070 |
Why?
|
| High-Throughput Screening Assays | 1 | 2009 | 80 | 0.070 |
Why?
|
| Interferon-alpha | 1 | 2009 | 101 | 0.070 |
Why?
|
| Leukocyte Count | 2 | 1999 | 102 | 0.070 |
Why?
|
| Models, Animal | 3 | 2006 | 242 | 0.070 |
Why?
|
| Genetic Predisposition to Disease | 2 | 2010 | 735 | 0.070 |
Why?
|
| Up-Regulation | 4 | 2009 | 376 | 0.070 |
Why?
|
| Dose-Response Relationship, Drug | 3 | 2007 | 858 | 0.070 |
Why?
|
| Homeostasis | 1 | 2010 | 383 | 0.070 |
Why?
|
| Quality of Life | 1 | 2015 | 1265 | 0.070 |
Why?
|
| Sequence Alignment | 2 | 2003 | 301 | 0.070 |
Why?
|
| Interleukin-6 | 4 | 2001 | 323 | 0.070 |
Why?
|
| Recombinant Fusion Proteins | 3 | 1999 | 503 | 0.070 |
Why?
|
| Resistin | 2 | 2004 | 7 | 0.070 |
Why?
|
| Immunity, Innate | 3 | 2009 | 829 | 0.060 |
Why?
|
| Shock, Septic | 3 | 1997 | 89 | 0.060 |
Why?
|
| Membrane Proteins | 2 | 2000 | 926 | 0.060 |
Why?
|
| Transfection | 3 | 2004 | 700 | 0.060 |
Why?
|
| Immune Tolerance | 4 | 2016 | 186 | 0.060 |
Why?
|
| Immune System Diseases | 1 | 2007 | 19 | 0.060 |
Why?
|
| Follow-Up Studies | 3 | 2015 | 2496 | 0.060 |
Why?
|
| Endothelium, Vascular | 3 | 2003 | 179 | 0.060 |
Why?
|
| CD4 Antigens | 2 | 1999 | 149 | 0.060 |
Why?
|
| Polymerase Chain Reaction | 3 | 2003 | 514 | 0.060 |
Why?
|
| Receptor-CD3 Complex, Antigen, T-Cell | 2 | 2004 | 3 | 0.060 |
Why?
|
| Interleukin-2 | 3 | 2001 | 167 | 0.060 |
Why?
|
| Research Design | 1 | 2009 | 590 | 0.060 |
Why?
|
| Bacterial Toxins | 2 | 1996 | 58 | 0.060 |
Why?
|
| 5' Untranslated Regions | 2 | 2004 | 28 | 0.060 |
Why?
|
| In Vitro Techniques | 5 | 2009 | 491 | 0.060 |
Why?
|
| Gene Silencing | 1 | 2009 | 436 | 0.060 |
Why?
|
| Cloning, Molecular | 2 | 2004 | 386 | 0.060 |
Why?
|
| B-Lymphocytes | 1 | 2009 | 565 | 0.060 |
Why?
|
| Drug Design | 1 | 2007 | 138 | 0.060 |
Why?
|
| Transglutaminases | 2 | 2018 | 14 | 0.060 |
Why?
|
| Blood Glucose Self-Monitoring | 2 | 2018 | 62 | 0.060 |
Why?
|
| Rabbits | 2 | 2003 | 342 | 0.060 |
Why?
|
| Acute Disease | 3 | 2002 | 663 | 0.060 |
Why?
|
| Muromonab-CD3 | 1 | 2005 | 7 | 0.060 |
Why?
|
| Vaccines, DNA | 2 | 2014 | 98 | 0.060 |
Why?
|
| Infant | 1 | 2010 | 1711 | 0.060 |
Why?
|
| Retinitis | 1 | 2005 | 6 | 0.060 |
Why?
|
| Introns | 2 | 2004 | 114 | 0.060 |
Why?
|
| Clinical Trials, Phase II as Topic | 1 | 2005 | 27 | 0.060 |
Why?
|
| Lymphocyte Culture Test, Mixed | 2 | 2003 | 35 | 0.060 |
Why?
|
| Risk Factors | 3 | 2010 | 5466 | 0.060 |
Why?
|
| Monitoring, Physiologic | 2 | 2016 | 169 | 0.050 |
Why?
|
| Age Factors | 2 | 2010 | 1592 | 0.050 |
Why?
|
| Moloney murine leukemia virus | 1 | 2024 | 17 | 0.050 |
Why?
|
| Uveitis | 1 | 2005 | 34 | 0.050 |
Why?
|
| Receptors, IgG | 1 | 2004 | 41 | 0.050 |
Why?
|
| Herpes Simplex | 1 | 2024 | 49 | 0.050 |
Why?
|
| Immunization, Passive | 1 | 2004 | 97 | 0.050 |
Why?
|
| Genetic Vectors | 2 | 2009 | 929 | 0.050 |
Why?
|
| Autonomic Nervous System Diseases | 1 | 2004 | 21 | 0.050 |
Why?
|
| Oligonucleotides | 2 | 2004 | 229 | 0.050 |
Why?
|
| Angiography, Digital Subtraction | 1 | 2004 | 140 | 0.050 |
Why?
|
| Monitoring, Intraoperative | 1 | 2004 | 47 | 0.050 |
Why?
|
| Lymphocyte Depletion | 3 | 2003 | 96 | 0.050 |
Why?
|
| Injections, Intra-Arterial | 1 | 2004 | 21 | 0.050 |
Why?
|
| Epstein-Barr Virus Infections | 1 | 2005 | 105 | 0.050 |
Why?
|
| Lymphocytic choriomeningitis virus | 2 | 2014 | 88 | 0.050 |
Why?
|
| History, 19th Century | 1 | 2003 | 40 | 0.050 |
Why?
|
| Tissue and Organ Procurement | 1 | 2004 | 40 | 0.050 |
Why?
|
| Bias | 1 | 2004 | 117 | 0.050 |
Why?
|
| Herpesvirus 4, Human | 1 | 2005 | 199 | 0.050 |
Why?
|
| Receptors, Interleukin-2 | 1 | 2003 | 71 | 0.050 |
Why?
|
| Antibodies, Neoplasm | 1 | 2003 | 27 | 0.050 |
Why?
|
| Recombinant Proteins | 2 | 2003 | 709 | 0.050 |
Why?
|
| Waiting Lists | 1 | 2003 | 55 | 0.050 |
Why?
|
| Self Efficacy | 1 | 2024 | 206 | 0.050 |
Why?
|
| Enzyme Activation | 3 | 2018 | 391 | 0.050 |
Why?
|
| Longevity | 1 | 2004 | 119 | 0.050 |
Why?
|
| Text Messaging | 1 | 2024 | 98 | 0.050 |
Why?
|
| Interleukin-3 | 2 | 2000 | 20 | 0.050 |
Why?
|
| Rats, Inbred Lew | 1 | 2023 | 106 | 0.050 |
Why?
|
| Mice, SCID | 3 | 2011 | 518 | 0.050 |
Why?
|
| Islet Amyloid Polypeptide | 1 | 2002 | 2 | 0.050 |
Why?
|
| Capillaries | 1 | 2002 | 35 | 0.050 |
Why?
|
| Proprotein Convertases | 1 | 2002 | 4 | 0.050 |
Why?
|
| Transplantation Conditioning | 1 | 2003 | 101 | 0.050 |
Why?
|
| Lupus Erythematosus, Systemic | 1 | 2004 | 183 | 0.050 |
Why?
|
| Granulocyte-Macrophage Colony-Stimulating Factor | 2 | 2000 | 74 | 0.050 |
Why?
|
| Stem Cells | 1 | 2024 | 276 | 0.050 |
Why?
|
| Mycophenolic Acid | 2 | 2001 | 68 | 0.050 |
Why?
|
| Response Elements | 1 | 2002 | 41 | 0.050 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 1 | 2003 | 157 | 0.050 |
Why?
|
| Concanavalin A | 2 | 2001 | 40 | 0.050 |
Why?
|
| Sequence Homology, Amino Acid | 1 | 2003 | 364 | 0.050 |
Why?
|
| Aspartic Acid Endopeptidases | 1 | 2002 | 37 | 0.050 |
Why?
|
| Salvage Therapy | 1 | 2002 | 75 | 0.050 |
Why?
|
| Interleukins | 2 | 2000 | 88 | 0.050 |
Why?
|
| Survival Analysis | 1 | 2003 | 579 | 0.050 |
Why?
|
| Leishmaniasis, Cutaneous | 2 | 1999 | 17 | 0.050 |
Why?
|
| Dependovirus | 1 | 2009 | 760 | 0.050 |
Why?
|
| Neuropeptides | 1 | 2002 | 81 | 0.040 |
Why?
|
| Neovascularization, Physiologic | 1 | 2002 | 113 | 0.040 |
Why?
|
| Organ Size | 1 | 2002 | 174 | 0.040 |
Why?
|
| Platelet Transfusion | 1 | 2001 | 12 | 0.040 |
Why?
|
| Macrophages | 2 | 2016 | 1041 | 0.040 |
Why?
|
| Amyloid | 1 | 2002 | 74 | 0.040 |
Why?
|
| Mice, Knockout | 4 | 2015 | 2168 | 0.040 |
Why?
|
| Cercopithecidae | 1 | 2001 | 1 | 0.040 |
Why?
|
| Blood Transfusion | 1 | 2003 | 167 | 0.040 |
Why?
|
| Cell Line | 4 | 2009 | 2030 | 0.040 |
Why?
|
| Proportional Hazards Models | 1 | 2003 | 746 | 0.040 |
Why?
|
| Tetradecanoylphorbol Acetate | 2 | 1999 | 62 | 0.040 |
Why?
|
| Caspase 3 | 2 | 2017 | 108 | 0.040 |
Why?
|
| Surveys and Questionnaires | 1 | 2009 | 2789 | 0.040 |
Why?
|
| Histocompatibility Antigens Class I | 2 | 2001 | 143 | 0.040 |
Why?
|
| Injections, Intraperitoneal | 1 | 2001 | 47 | 0.040 |
Why?
|
| Blotting, Western | 1 | 2002 | 611 | 0.040 |
Why?
|
| Heterozygote | 2 | 2018 | 173 | 0.040 |
Why?
|
| NAD+ Nucleosidase | 1 | 2000 | 10 | 0.040 |
Why?
|
| Health Behavior | 1 | 2024 | 485 | 0.040 |
Why?
|
| Pilot Projects | 1 | 2024 | 1026 | 0.040 |
Why?
|
| Blood Platelets | 1 | 2001 | 108 | 0.040 |
Why?
|
| Cell Division | 4 | 2003 | 451 | 0.040 |
Why?
|
| Acinar Cells | 1 | 2020 | 8 | 0.040 |
Why?
|
| Embolization, Therapeutic | 1 | 2004 | 337 | 0.040 |
Why?
|
| Superantigens | 2 | 1996 | 9 | 0.040 |
Why?
|
| Bone Marrow Cells | 1 | 2000 | 237 | 0.040 |
Why?
|
| Enterotoxins | 2 | 1996 | 20 | 0.040 |
Why?
|
| Thymus Gland | 1 | 2001 | 240 | 0.040 |
Why?
|
| Postprandial Period | 2 | 2013 | 20 | 0.040 |
Why?
|
| Hyperinsulinism | 2 | 2010 | 26 | 0.040 |
Why?
|
| Protein Kinase C | 3 | 1999 | 102 | 0.040 |
Why?
|
| fas Receptor | 1 | 2000 | 56 | 0.040 |
Why?
|
| Proto-Oncogene Proteins | 2 | 1999 | 344 | 0.040 |
Why?
|
| L-Selectin | 1 | 1999 | 14 | 0.040 |
Why?
|
| Registries | 2 | 2013 | 934 | 0.040 |
Why?
|
| Intracellular Fluid | 1 | 1999 | 32 | 0.040 |
Why?
|
| Killer Cells, Natural | 1 | 2000 | 220 | 0.040 |
Why?
|
| T-Lymphocytes, Regulatory | 2 | 1998 | 222 | 0.040 |
Why?
|
| Reproducibility of Results | 1 | 2003 | 1715 | 0.040 |
Why?
|
| Cell Movement | 1 | 2001 | 484 | 0.040 |
Why?
|
| Rats, Inbred BB | 1 | 1998 | 134 | 0.030 |
Why?
|
| Blotting, Northern | 2 | 2004 | 152 | 0.030 |
Why?
|
| Gene Transfer Techniques | 1 | 2000 | 325 | 0.030 |
Why?
|
| Ligands | 1 | 1999 | 414 | 0.030 |
Why?
|
| Insecta | 1 | 2018 | 36 | 0.030 |
Why?
|
| Inflammation | 2 | 2023 | 1195 | 0.030 |
Why?
|
| Telephone | 1 | 2018 | 123 | 0.030 |
Why?
|
| Cellular Reprogramming | 1 | 2018 | 41 | 0.030 |
Why?
|
| Carrier Proteins | 1 | 2002 | 718 | 0.030 |
Why?
|
| DNA Primers | 2 | 1998 | 302 | 0.030 |
Why?
|
| Protein-Arginine Deiminases | 1 | 2018 | 91 | 0.030 |
Why?
|
| GTP-Binding Proteins | 1 | 2018 | 93 | 0.030 |
Why?
|
| Capillary Resistance | 1 | 2017 | 2 | 0.030 |
Why?
|
| Models, Organizational | 1 | 2018 | 93 | 0.030 |
Why?
|
| Leukocytes, Mononuclear | 1 | 1998 | 248 | 0.030 |
Why?
|
| Microvessels | 1 | 2017 | 18 | 0.030 |
Why?
|
| Spleen | 1 | 1998 | 476 | 0.030 |
Why?
|
| Bionics | 1 | 2016 | 3 | 0.030 |
Why?
|
| Drug Synergism | 1 | 1997 | 142 | 0.030 |
Why?
|
| Child, Preschool | 2 | 2015 | 2076 | 0.030 |
Why?
|
| Immunization | 3 | 2005 | 135 | 0.030 |
Why?
|
| Adoptive Transfer | 3 | 2005 | 145 | 0.030 |
Why?
|
| Microfluidics | 1 | 2016 | 26 | 0.030 |
Why?
|
| Gene Library | 1 | 2016 | 102 | 0.030 |
Why?
|
| Ambulatory Care | 1 | 2018 | 318 | 0.030 |
Why?
|
| Nausea | 1 | 2016 | 111 | 0.030 |
Why?
|
| Mutation | 1 | 2024 | 2672 | 0.030 |
Why?
|
| Clone Cells | 1 | 2016 | 111 | 0.030 |
Why?
|
| Transcription Factors | 3 | 2018 | 1561 | 0.030 |
Why?
|
| Rodentia | 1 | 2015 | 20 | 0.030 |
Why?
|
| Glycogen Synthase Kinase 3 beta | 1 | 2015 | 36 | 0.030 |
Why?
|
| Glycosuria | 1 | 1995 | 3 | 0.030 |
Why?
|
| Genotype | 3 | 2002 | 674 | 0.030 |
Why?
|
| Translocation, Genetic | 1 | 2015 | 74 | 0.030 |
Why?
|
| Sampling Studies | 1 | 2015 | 65 | 0.030 |
Why?
|
| Administration, Oral | 2 | 2009 | 371 | 0.030 |
Why?
|
| Pregnancy Trimester, Second | 1 | 2015 | 36 | 0.030 |
Why?
|
| CD8 Antigens | 1 | 1994 | 53 | 0.030 |
Why?
|
| Postoperative Care | 1 | 2015 | 125 | 0.030 |
Why?
|
| Disease Susceptibility | 1 | 1995 | 169 | 0.030 |
Why?
|
| Biocompatible Materials | 1 | 2016 | 154 | 0.030 |
Why?
|
| Freund's Adjuvant | 1 | 2014 | 14 | 0.030 |
Why?
|
| Decision Making | 1 | 2018 | 429 | 0.030 |
Why?
|
| Diabetic Ketoacidosis | 1 | 2013 | 13 | 0.020 |
Why?
|
| Fasting | 1 | 2013 | 52 | 0.020 |
Why?
|
| Antigens, Viral | 1 | 1994 | 130 | 0.020 |
Why?
|
| Immunity, Cellular | 1 | 1994 | 170 | 0.020 |
Why?
|
| Schizophrenia | 1 | 2015 | 275 | 0.020 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2014 | 420 | 0.020 |
Why?
|
| Interdisciplinary Communication | 1 | 2013 | 106 | 0.020 |
Why?
|
| Glycoproteins | 1 | 2014 | 189 | 0.020 |
Why?
|
| S100 Calcium Binding Protein beta Subunit | 1 | 2012 | 8 | 0.020 |
Why?
|
| Mice, Inbred BALB C | 3 | 1999 | 869 | 0.020 |
Why?
|
| S100 Proteins | 1 | 2012 | 20 | 0.020 |
Why?
|
| Iodide Peroxidase | 1 | 2012 | 23 | 0.020 |
Why?
|
| Telemedicine | 1 | 2018 | 376 | 0.020 |
Why?
|
| Nerve Growth Factors | 1 | 2012 | 28 | 0.020 |
Why?
|
| Potassium Channels | 1 | 2012 | 55 | 0.020 |
Why?
|
| Immunoprecipitation | 1 | 2012 | 128 | 0.020 |
Why?
|
| Isoantibodies | 2 | 2003 | 35 | 0.020 |
Why?
|
| Luciferases | 1 | 2012 | 107 | 0.020 |
Why?
|
| Health Services Accessibility | 1 | 2018 | 603 | 0.020 |
Why?
|
| Viral Proteins | 1 | 2014 | 272 | 0.020 |
Why?
|
| Cell Differentiation | 3 | 2007 | 1389 | 0.020 |
Why?
|
| Myristoylated Alanine-Rich C Kinase Substrate | 1 | 1991 | 2 | 0.020 |
Why?
|
| HLA Antigens | 1 | 2011 | 62 | 0.020 |
Why?
|
| Coculture Techniques | 2 | 2002 | 104 | 0.020 |
Why?
|
| Lipids | 1 | 2014 | 330 | 0.020 |
Why?
|
| Interleukin Receptor Common gamma Subunit | 1 | 2011 | 81 | 0.020 |
Why?
|
| Fluorescent Antibody Technique | 2 | 2003 | 233 | 0.020 |
Why?
|
| Sequence Homology, Nucleic Acid | 1 | 1991 | 111 | 0.020 |
Why?
|
| Evidence-Based Medicine | 1 | 2013 | 464 | 0.020 |
Why?
|
| Chickens | 1 | 1991 | 94 | 0.020 |
Why?
|
| Retrospective Studies | 1 | 2003 | 6948 | 0.020 |
Why?
|
| Pancreatectomy | 2 | 2003 | 99 | 0.020 |
Why?
|
| Interleukin-10 | 2 | 2002 | 165 | 0.020 |
Why?
|
| Postoperative Period | 2 | 2002 | 130 | 0.020 |
Why?
|
| Cattle | 1 | 1991 | 320 | 0.020 |
Why?
|
| Statistics, Nonparametric | 1 | 2011 | 213 | 0.020 |
Why?
|
| Adenosine Triphosphatases | 1 | 2012 | 256 | 0.020 |
Why?
|
| Plasmids | 1 | 1991 | 294 | 0.020 |
Why?
|
| Thymidine | 1 | 2010 | 25 | 0.020 |
Why?
|
| Incretins | 1 | 2010 | 8 | 0.020 |
Why?
|
| Sulfonylurea Compounds | 1 | 2010 | 12 | 0.020 |
Why?
|
| Alleles | 2 | 2002 | 455 | 0.020 |
Why?
|
| Chromosome Mapping | 1 | 1991 | 297 | 0.020 |
Why?
|
| Receptor, IGF Type 1 | 1 | 2010 | 30 | 0.020 |
Why?
|
| Severity of Illness Index | 1 | 2015 | 1567 | 0.020 |
Why?
|
| Receptor, Insulin | 1 | 2010 | 52 | 0.020 |
Why?
|
| Thiazolidinediones | 1 | 2010 | 50 | 0.020 |
Why?
|
| Estrogens | 1 | 2010 | 115 | 0.020 |
Why?
|
| Testosterone | 1 | 2010 | 128 | 0.020 |
Why?
|
| Dissection | 1 | 2009 | 47 | 0.020 |
Why?
|
| Placebos | 1 | 2009 | 73 | 0.020 |
Why?
|
| Cell Separation | 1 | 2009 | 147 | 0.020 |
Why?
|
| Cell Line, Tumor | 2 | 2004 | 1573 | 0.020 |
Why?
|
| Disease Progression | 1 | 2014 | 1227 | 0.020 |
Why?
|
| Metformin | 1 | 2010 | 77 | 0.020 |
Why?
|
| Prevalence | 1 | 2013 | 1453 | 0.020 |
Why?
|
| Antibodies, Antinuclear | 1 | 2009 | 41 | 0.020 |
Why?
|
| Transcription Factor RelB | 2 | 1999 | 6 | 0.020 |
Why?
|
| Hypoxia-Inducible Factor 1, alpha Subunit | 1 | 2009 | 38 | 0.020 |
Why?
|
| Rats, Wistar | 1 | 2009 | 184 | 0.020 |
Why?
|
| Immunologic Factors | 1 | 2009 | 108 | 0.020 |
Why?
|
| Risk Assessment | 1 | 2015 | 2113 | 0.020 |
Why?
|
| Overweight | 1 | 2010 | 254 | 0.020 |
Why?
|
| Pregnancy | 1 | 2015 | 2393 | 0.020 |
Why?
|
| Mass Screening | 1 | 2013 | 700 | 0.020 |
Why?
|
| Cell Lineage | 1 | 2009 | 282 | 0.020 |
Why?
|
| Motor Activity | 1 | 2010 | 346 | 0.020 |
Why?
|
| Double-Blind Method | 1 | 2009 | 745 | 0.020 |
Why?
|
| Alcohol Drinking | 1 | 2010 | 325 | 0.020 |
Why?
|
| Sex Factors | 1 | 2010 | 995 | 0.020 |
Why?
|
| Pancreatitis-Associated Proteins | 1 | 2006 | 5 | 0.020 |
Why?
|
| Pancreatic Elastase | 1 | 2006 | 32 | 0.020 |
Why?
|
| Peptide Hormones | 1 | 2006 | 8 | 0.020 |
Why?
|
| Depression | 1 | 2013 | 908 | 0.020 |
Why?
|
| Diet | 1 | 2010 | 536 | 0.020 |
Why?
|
| Cell Adhesion | 1 | 2007 | 218 | 0.020 |
Why?
|
| Body Mass Index | 1 | 2010 | 900 | 0.010 |
Why?
|
| In Situ Hybridization | 1 | 2006 | 213 | 0.010 |
Why?
|
| Incidence | 1 | 2010 | 1432 | 0.010 |
Why?
|
| Cohort Studies | 1 | 2012 | 2639 | 0.010 |
Why?
|
| Cross-Sectional Studies | 1 | 2013 | 2730 | 0.010 |
Why?
|
| Retinol-Binding Proteins | 1 | 2005 | 4 | 0.010 |
Why?
|
| Smoking | 1 | 2010 | 863 | 0.010 |
Why?
|
| Homeodomain Proteins | 1 | 2007 | 277 | 0.010 |
Why?
|
| Luminescent Measurements | 1 | 2005 | 40 | 0.010 |
Why?
|
| Eye Proteins | 1 | 2005 | 73 | 0.010 |
Why?
|
| Trans-Activators | 1 | 2007 | 321 | 0.010 |
Why?
|
| Subcellular Fractions | 1 | 2004 | 67 | 0.010 |
Why?
|
| Thrombocythemia, Essential | 1 | 2004 | 3 | 0.010 |
Why?
|
| Species Specificity | 1 | 2005 | 344 | 0.010 |
Why?
|
| Microscopy, Confocal | 1 | 2005 | 240 | 0.010 |
Why?
|
| Hemorrhage | 1 | 2006 | 286 | 0.010 |
Why?
|
| Glycosylation | 1 | 2004 | 139 | 0.010 |
Why?
|
| Nerve Growth Factor | 1 | 2003 | 5 | 0.010 |
Why?
|
| RNA, Neoplasm | 1 | 2003 | 36 | 0.010 |
Why?
|
| Exons | 1 | 2004 | 208 | 0.010 |
Why?
|
| Area Under Curve | 1 | 2004 | 149 | 0.010 |
Why?
|
| Alemtuzumab | 1 | 2003 | 11 | 0.010 |
Why?
|
| Glucagon-Like Peptide 1 | 1 | 2003 | 30 | 0.010 |
Why?
|
| Reference Values | 1 | 2004 | 328 | 0.010 |
Why?
|
| Graft Enhancement, Immunologic | 1 | 2003 | 10 | 0.010 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 1 | 2003 | 104 | 0.010 |
Why?
|
| Immunologic Memory | 1 | 2005 | 284 | 0.010 |
Why?
|
| Indoles | 1 | 2003 | 112 | 0.010 |
Why?
|
| Injections, Intravenous | 1 | 2003 | 160 | 0.010 |
Why?
|
| Imaging, Three-Dimensional | 1 | 2005 | 300 | 0.010 |
Why?
|
| Colony-Forming Units Assay | 1 | 2002 | 26 | 0.010 |
Why?
|
| CD4-CD8 Ratio | 1 | 2002 | 16 | 0.010 |
Why?
|
| Renal Insufficiency | 1 | 2002 | 68 | 0.010 |
Why?
|
| Lymph Nodes | 1 | 2003 | 237 | 0.010 |
Why?
|
| Caspases | 1 | 2003 | 176 | 0.010 |
Why?
|
| RNA, Small Interfering | 1 | 2009 | 990 | 0.010 |
Why?
|
| Evaluation Studies as Topic | 1 | 2002 | 105 | 0.010 |
Why?
|
| P-Selectin | 1 | 2001 | 7 | 0.010 |
Why?
|
| Kinetics | 1 | 2004 | 757 | 0.010 |
Why?
|
| Thrombin | 1 | 2001 | 23 | 0.010 |
Why?
|
| Fluorescent Dyes | 1 | 2003 | 204 | 0.010 |
Why?
|
| Antibody Specificity | 1 | 2001 | 103 | 0.010 |
Why?
|
| Cell Survival | 1 | 2003 | 588 | 0.010 |
Why?
|
| Intestine, Small | 1 | 2002 | 84 | 0.010 |
Why?
|
| Gene Frequency | 1 | 2001 | 124 | 0.010 |
Why?
|
| Dose-Response Relationship, Immunologic | 1 | 2001 | 50 | 0.010 |
Why?
|
| Leukemia Virus, Gibbon Ape | 1 | 2000 | 1 | 0.010 |
Why?
|
| ADP-ribosyl Cyclase | 1 | 2000 | 5 | 0.010 |
Why?
|
| Erythema | 1 | 2001 | 14 | 0.010 |
Why?
|
| Aged | 2 | 2010 | 15090 | 0.010 |
Why?
|
| Biopsy | 1 | 2002 | 460 | 0.010 |
Why?
|
| Stem Cell Factor | 1 | 2000 | 27 | 0.010 |
Why?
|
| ADP-ribosyl Cyclase 1 | 1 | 2000 | 26 | 0.010 |
Why?
|
| Transplantation, Autologous | 1 | 2001 | 128 | 0.010 |
Why?
|
| Retroviridae | 1 | 2000 | 75 | 0.010 |
Why?
|
| Receptors, Virus | 1 | 2000 | 73 | 0.010 |
Why?
|
| Cross Reactions | 1 | 2000 | 140 | 0.010 |
Why?
|
| Perforin | 1 | 2000 | 26 | 0.010 |
Why?
|
| Receptors, Tumor Necrosis Factor, Type II | 1 | 2000 | 29 | 0.010 |
Why?
|
| Pore Forming Cytotoxic Proteins | 1 | 2000 | 34 | 0.010 |
Why?
|
| Receptors, Tumor Necrosis Factor | 1 | 2000 | 64 | 0.010 |
Why?
|
| Major Histocompatibility Complex | 1 | 2000 | 85 | 0.010 |
Why?
|
| Papio | 1 | 1999 | 22 | 0.010 |
Why?
|
| Cell Culture Techniques | 1 | 2000 | 195 | 0.010 |
Why?
|
| Microscopy, Electron | 1 | 2000 | 254 | 0.010 |
Why?
|
| Tumor Cells, Cultured | 1 | 2000 | 426 | 0.010 |
Why?
|
| Interleukin-12 | 1 | 1999 | 127 | 0.010 |
Why?
|
| T-Lymphocytes, Helper-Inducer | 1 | 1999 | 112 | 0.010 |
Why?
|
| Immunophenotyping | 1 | 1999 | 194 | 0.010 |
Why?
|
| Cell Cycle | 1 | 2000 | 398 | 0.010 |
Why?
|
| Macromolecular Substances | 1 | 1999 | 162 | 0.010 |
Why?
|
| Th2 Cells | 1 | 1998 | 93 | 0.010 |
Why?
|
| Interleukin-4 | 1 | 1998 | 147 | 0.010 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2006 | 1662 | 0.010 |
Why?
|
| Th1 Cells | 1 | 1998 | 171 | 0.010 |
Why?
|
| DNA, Complementary | 1 | 1998 | 165 | 0.010 |
Why?
|
| Crosses, Genetic | 1 | 1996 | 116 | 0.010 |
Why?
|
| Receptors, Antigen, T-Cell, alpha-beta | 1 | 1996 | 112 | 0.010 |
Why?
|
| Staphylococcus aureus | 1 | 1996 | 183 | 0.010 |
Why?
|
| Immunoglobulins, Intravenous | 1 | 1994 | 34 | 0.010 |
Why?
|